Sti-6129

Advanced Solid Tumor

Sorrento Therapeutics, Inc.antibody_drug_conjugatePhase 1Active

C

36/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 59/ 100

Competitive context

1411 Active assets in the Advanced Solid Tumor cohort.

Asset / Sponsor	Phase	Rating
Nabiximols Jazz Pharmaceuticals	Phase 3	BBB
Inno-206 M.D. Anderson Cancer Center	Phase 2	BB
Vitamin B6 M.D. Anderson Cancer Center	Phase 4	BB
PROPOFOL Hong Kong Children's Hospital	Phase 4	BB
Rivoceranib Jiangsu HengRui Medicine Co., Ltd.	Phase 4	BB

View all 50 →

Same molecule, other indications

Sti-6129 is also rated in:

refractory precursor T-lymphoblastic lymphoma/leukemiaDormant

CC

Indicative ·

43 / 100

acute myeloid leukemiaDormant

CC

Indicative ·

41 / 100

plasma cell myelomaDormant

CC

Indicative ·

40 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.